News
Sarepta Therapeutics is refusing to pull its gene therapy Elevidys (delandistrogene moxeparvovec), despite a request from the FDA.
Sarepta said it accepts the CHMP decision on Elevidys, while partner Roche said it will continue working with the EMA.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback